Insider Purchases: Inside the Buy

Tag: hub-epiphany

DNA stock chart tug-of-war between shorts and insider buyers for Intellia (NTLA).

Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?

NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.

Read entire article

Tags: Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, biotech jokes, Biotech Picks, buy-or-sell-ntla, clinical-trials, CRISPR, CRISPR Gene Editing, death-in-trial, fda, fda-hold, featured-epiphany, featured-insiders, funstock-index, gene-editing, healthcare-stocks, high-risk-high-reward, hub-epiphany, hub-insiders, insider-buys, Intellia Therapeutics, nasdaq, Ntla, risks-buying-ntla, short-interest, speculative-stocks, spotlight-health, why-buy-ntla
Illustration of a stylized crown hovering above biotech molecules and financial charts, representing XOMA Royalty’s strategy of collecting biotech royalties without developing drugs.

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article

Tags: Biotech Royalties, Biotech Stocks, buy-or-sell-XOMA, CEO buy, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, featured-insiders, funanc1al edge, funanc1al humor, FUNanc1al Investing, FUNstock Income + Growth, Healthcare Investing, hub-diversify, hub-epiphany, hub-fun, hub-hedge, hub-insiders, hub-ipos, hub-overseas, hub-ridiculous, hub-special-files, hub-value, Insider Buying, risks-investing-in-xoma, Royalty Stocks, Small-Cap Stocks, why-buy-xoma, XOMA, XOMA Royalty